Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hepatitis Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hepatitis Other
    Model Predicts Outcomes of Pegylated Interferon Therapy in Patients With Chronic Hepatitis B: Presented at AASLD - (DGDispatch)
    Long-Term Entecavir May Reverse Liver Damage in Patients With Chronic Hepatitis B Infection: Presented at AASLD - (DGDispatch)
    Lamivudine-Resistant Mutation Among Treatment-Naïve Hepatitis B Patients May Be Associated With Treatment Failure: Presented at AASLD - (DGDispatch)
    Telbivudine Efficacy Maintained for 3 Years in Patients With Chronic Hepatitis B: Presented at AASLD - (DGDispatch)
    Long-Term Efficacy Shown With Entecavir for Patients With Chronic Hepatitis B: Presented at AASLD - (DGDispatch)

    News archive

     Recent webcasts/CME - Hepatitis Other
    • Optimizing Treatment for Chronic HBV: New Data on Management Options
    • Nucleoside Analogs Lead to Long-Term Responses in Chronic Hepatitis B
    • The ABC's of Viral Hepatitis
      Chronic Hepatitis B Virus Infection: Review and Update
      Delivering Optimal Care: Prevention, Detection, and Management of Hepatitis B in Asian and Pacific Islander Americans

      Webcasts/CME archive

       Recent cases - Hepatitis Other
        Severe Hepatitis with Autoimmune Features Following a HHV-6: A Case Report
        Severe Hemolytic Anemia as the First Manifestation of G6PD Deficiency in a Child with Acute Hepatitis A Infection
        Cholestatic Hepatitis as a Possible New Side-Effect of Oxycodone: A Case Report
        Sustained Virological and Biochemical Responses to Lamivudine and Adefovir Dipivoxil Combination in a Chronic Hepatitis B Infection Despite Mutations Conferring Resistance to Both Drugs
        Nitrofurantoin-Induced Chronic Active Hepatitis in an Elderly Woman

        Cases archive
          




        my personal edition > hepatitis other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Long-Term Treatment of HBeAg-Positive Chronic Hepatitis B Patients With Adefovir Dipivoxil Safe and Effective: Presented at AASLD

        By Maria Bishop

        BOSTON, MA -- November 1, 2006 -- Chronic hepatitis B patients who are hepatitis e antigen (HBeAg)-positive experienced significant virological and biochemical responses to long-term treatment with adefovir dipivoxil, researchers reported here at the 57th Annual Meeting of the American Society for Liver Diseases (AASLD).

        In addition, 3 years of treatment with 10 mg daily of adefovir dipivoxil was well tolerated, noted Yi-Min Mao, MD, department of gastroenterology, Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai, People's Republic of China.

        The presence of HBeAg in chronic infection generally indicates that hepatitis B virus is actively reproducing, and that there is a higher probability of liver damage.

        In a presentation on October 30th, Dr. Mao discussed the 3 years of data from a 1-year randomised, double-blind, placebo-controlled trial that enrolled 480 patients, and which is currently in the middle of a 4-year open-label extension phase with 474 patients and 456 patients for years 2 and 3, respectively.

        The study is taking place at 12 centers across China.

        During the first year of the randomised study, one third of subjects received placebo for the first 12 of 52 weeks (PAAA group); another third received placebo for the last 12 of 52 weeks (AAPA group). The final third cohort received continuous adefovir dipivoxil (AAAA group). Subjects had an average age of 30 years, and 83% were male.

        At 3 years, 15.4% of 480 achieved protocol-defined durable HBeAg seroconversion. The median off-drug follow-up was 36 weeks in the 62 patients who stopped adefovir therapy once durable HBeAg seroconversion was achieved. Thirteen patients restarted treatment due to virologic breakthrough within 30 weeks.

        At this time, 1% of subjects -- all in the AAAA group -- demonstrated HBsAg loss; 4 subjects demonstrated HBsAg seroconversion. Similarly, in the AAAA group, at week 52 adefovir therapy showed significant improvement of quality of life.

        There is great concern today over resistance to hepatitis B treatments, noted Dr. Mao, but resistance mutations were identified in only 3% of 456 subjects up to this time (N236T or A181V ADV mutations).

        No data indicate any renal safety concerns, although serious adverse events occurred in 5% of all subjects, which Dr. Mao considers to be drug-related. Seven patients discontinued this study due to adverse events before the open-label extension began.


        [Presentation title: Efficacy and Safety of Three Years Therapy With Adefovir Dipivoxil (ADV) in Chinese Subjects With HBeAg-Positive Chronic Hepatitis B (CHB). Abstract LB21]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send